Compare Global X Copper Miners ETF (COPX) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Novavax Inc — how do they compare? Global X Copper Miners ETF trades at $85.75 (market cap $7.10B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Global X Copper Miners ETF is far larger — about 3.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and Novavax Inc for 59 Days on average.
| COPX | NVAX | |
|---|---|---|
Market Cap | $7.10B | $1.82B |
Volume | 2,871,128 | 6,198,505 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $12.56 |
52-Week Low | $57.43 | $6.22 |
Typical Hold Time | 51 Days | 59 Days |
Enterprise Value | — | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $85.75, up 2.6% with a bearish technical outlook from moving averages. The ETF faces mixed sentiment as copper demand surges due to AI and electrification trends, while miner stocks lag behind metal prices. Recent articles highlight copper's strategic importance but note global surplus concerns and Federal Reserve policy impacts on mining equities.
Outlook hinges on copper price sustainability amid AI-driven demand, though miner valuations remain pressured. Key risks include global copper surplus projections and Fed policy volatility. Opportunities exist from structural copper deficits and operational leverage if metal prices hold near record highs above $6.85/lb (GuruFocus, September 8, 2026).
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
